​

Biohaven Stock (NYSE:BHVN)

ForecastOwnershipFinancialsChart
Biohaven by TradingView

Previous Close

$11.07

52W Range

$7.48 - $18.57

50D Avg

$9.97

200D Avg

$11.64

Market Cap

$1.20B

Avg Vol (3M)

$2.33M

Beta

3.31

Div Yield

-

BHVN Company Profile

Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

256

IPO Date

Sep 23, 2022

Website

BHVN Performance

BHVN Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-745.38M$-885.11M$-436.05M
Net Income$-738.82M$-846.42M$-408.17M
EBITDA$-745.38M$-877.26M$-429.14M
Basic EPS$-6.86$-9.28$-5.73
Diluted EPS$-6.86$-9.28$-5.73

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 21Feb 25, 22 | 8:30 AM
Q3 21Nov 09, 21 | 1:08 PM
Q2 21Aug 09, 21 | 8:30 AM

Peer Comparison

TickerCompany
PHVSPharvaris N.V.
SIONSionna Therapeutics, Inc.
XERSXeris Biopharma Holdings, Inc.
ABCLAbCellera Biologics Inc.
IMCRImmunocore Holdings plc
CLDXCelldex Therapeutics, Inc.
NTLAIntellia Therapeutics, Inc.
VERAVera Therapeutics, Inc.
IMNMImmunome, Inc.
ZBIOZenas BioPharma, Inc.